Your session is about to expire
← Back to Search
Adavosertib + Olaparib for Recurrent Ovarian Cancer
Study Summary
This trial is testing adavosertib with or without olaparib to treat patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 1 & 2 trial • 76 Patients • NCT02095132Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not had a blood transfusion in the last 4 months.I do not have a serious infection or condition that would stop me from receiving the study treatment.I cannot swallow pills or have a stomach condition that affects medication absorption.I have not had serious heart problems in the last 6 months.My heart's electrical activity (QTc interval) is normal.I have had a bone marrow or double umbilical cord blood transplant.I have heart conditions or family history that could affect my heart's rhythm.I have been diagnosed with myelodysplastic syndrome or acute myeloid leukemia.I am not taking any strong or moderate drugs that affect liver enzymes.My ovarian, peritoneal, or fallopian tube cancer has returned and cannot be cured with available treatments.My cancer is BRCA mutant or HRD positive.I took olaparib without major side effects or needing a lower dose.I have received previous treatments.I haven't had certain cancer treatments recently and follow specific medication rules.I have a history of issues that could affect blood flow to my brain.I have high blood pressure that needs treatment.I have been diagnosed with ataxia telangiectasia.I haven't had any cancer except for certain skin, cervical, or early breast cancers in the last 3 years.I don't have serious side effects from past treatments, except for hair loss or mild nerve pain.I am 18 years old or older.I haven't had major surgery in the last 28 days or minor surgery in the last 7 days.I have experienced side effects from previous treatments, but not hair loss or loss of appetite.I am not taking strong or moderate drugs that affect liver enzymes.I have used drugs that affect certain liver enzymes.I have treated brain metastases with no recent progression and stable health.I am not taking any drugs that affect CYP3A4 enzymes or can't stop them before the study.I have seen improvement with PARP inhibitor treatment for at least 6 months.My cancer progressed while on or soon after PARP inhibitor treatment.I have saved tissue samples from before my PARP inhibitor treatment.I am fully active or restricted in physically strenuous activity but can do light work.I am willing and able to follow the study's requirements.My cancer responded to platinum therapy and didn't return for over 6 months.My cancer progressed despite being on a PARP inhibitor treatment.My organs and bone marrow are functioning well.I have previously received PARP inhibitor therapy.
- Group 1: Arm III (ceralasertib, olaparib)
- Group 2: Arm I (adavosertib)
- Group 3: Arm II (olaparib, adavosertib)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this medical experiment introduce a new method of treatment?
"At present, 202 separate experiments utilizing Adavosertib are being conducted across 1629 cities and 60 nations. Initially studied in 2005 by AstraZeneca with 98 participants, the Phase 1 drug approval stage of this trial has been successfully completed. In the intervening years since then, 85 trials have finished their course."
What potential adverse outcomes might be associated with Adavosertib usage?
"Our experts rank the safety of Adavosertib as a 2, due to this Phase 2 trial having some data demonstrating its safe usage but none providing evidence for effectiveness."
Could you provide a synopsis of the research thus far conducted on Adavosertib?
"First studied in 2005, adavosertib has had 85 trials completed and over 200 ongoing investigations. Of those currently active studies, a significant portion are conducted within the Boston area of Massachusetts."
What medical conditions can be addressed with the use of Adavosertib?
"Adavosertib is typically prescribed to treat late-stage diseases, including malignant neoplasm of ovary, primary peritoneal cancer, and hallucinations with physical symptoms."
Are there any openings remaining for individuals to participate in this experiment?
"Affirmative. Clinicaltrials.gov reveals that this trial is currently seeking participants, having initially been posted on December 7th 2018 and last updated August 31st 2022. 104 individuals need to be recruited from two separate medical facilities."
How many individuals are being recruited to participate in this trial?
"Affirmative. Per the information housed on clinicaltrials.gov, this medical trial is actively accepting participants. The initial posting was made on December 7th 2018 and the listing has been updated as recently as August 31st 2022. This study requires 104 individuals to be recruited from two distinct sites."
Share this study with friends
Copy Link
Messenger